KDx Diagnostics And Lister Hospital Announce The Launch Of A Non-Invasive URO17® Urine Test For Bladder Cancer In The United Kingdom

December 7, 20210

SAN JOSE, Calif. and STEVENAGE, England, Dec. 5, 2021 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), and Lister Hospital (East and North Hertfordshire NHS Trust), Stevenage, UK, announced today the launch in the United Kingdom (UK) of KDx’s URO17® test for detection of bladder cancer. This non-invasive urine test for bladder cancer is highly sensitive for identifying bladder cancer in patients with hematuria and recurrent bladder cancer during post-treatment monitoring.  Click for more…

Leave a Reply

Your email address will not be published. Required fields are marked *